Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543780902832679 PMID 19335277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

  2008cited by this paper
• B cells flying solo

  2008cited by this paper
• Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.

  2008cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• Signals that maintain leukemic cell viability.

  2008cited by this paper
• Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti‐CD20 antibody

  2008cited by this paper
• Newer monoclonal antibodies for hematological malignancies.

  2008cited by this paper
• Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis1

  2008cited by this paper
• Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Natural history of multiple sclerosis in a population‐based cohort

  2008cited by this paper
• First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

  2008cited by this paper
• Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders.

  2008cited by this paper
• High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival.

  2008cited by this paper
• Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

  2007cited by this paper
• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

  2006cited by this paper
• Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

  2006cited by this paper
• The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201

  2006cited by this paper
• Lymphoma and the control of B cell growth and differentiation.

  2006cited by this paper
• Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

  2005cited by this paper
• The risk of lymphoma development in autoimmune diseases: a meta-analysis.

  2005cited by this paper
• Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

  2005cited by this paper
• Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

  2004cited by this paper
• Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

  2003cited by this paper
• Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.

  2002cited by this paper
• Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

  2001cited by this paper
• Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

  2000cited by this paper
• Characterization of a human B lymphocyte-specific antigen.

  1980cited by this paper

• A meaningful exploration of ofatumumab in refractory NMOSD: a case report

  2023cites this paper
• Immunotherapy for Pemphigus: Present and Future

  2022cites this paper
• Umbilical Cord Mesenchymal Stem Cell Therapy for Regenerative Treatment of Rheumatoid Arthritis: Opportunities and Challenges

  2021influential citation
• Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia

  2021cites this paper
• The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

  2021cites this paper
• DDDT_A_323107 3927..3936

  2021influential citation
• Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases—Implications for Therapeutic Approaches

  2020cites this paper
• Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm

  2020cites this paper
• Opuntioside, opuntiol and its metallic nanoparticles attenuate adjuvant-induced arthritis: Novel suppressors of Toll-like receptors -2 and -4.

  2019cites this paper
• The pathogenesis of bullous skin diseases

  2019cites this paper
• Human Monoclonal Antibodies: Methods and Protocols

  2019cites this paper
• Current Clinical Trials in Pemphigus and Pemphigoid

  2019cites this paper
• The applications of anti-CD20 antibodies to treat various B cells disorders.

  2019cites this paper
• A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT) lymphoma

  2018cites this paper
• Novel Therapies in Acute Lymphoblastic Leukemia

  2018cites this paper
• Gum acacia stabilized silver nanoparticles based nano-cargo for enhanced anti-arthritic potentials of hesperidin in adjuvant induced arthritic rats

  2018cites this paper
• Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

  2018cites this paper
• Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody

  2017cites this paper
• New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness

  2017cites this paper
• Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases.

  2016cites this paper
• Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice

  2015cites this paper
• Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates

  2015cites this paper
• Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis

  2014cites this paper
• B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

  2014cites this paper
• Advances in treating chronic lymphocytic leukemia

  2014cites this paper
• N-(2-hydroxy phenyl) acetamide: a novel suppressor of Toll-like receptors (TLR-2 and TLR-4) in adjuvant-induced arthritic rats

  2014cites this paper
• Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

  2014cites this paper
• Associated Glomerulonephritis-An In-Depth Review

  2014cites this paper
• Polyclonal and monoclonal antibodies in clinic.

  2014cites this paper
• Targeted therapy and outcome in chronic lymphocytic leukemia

  2014cites this paper
• B-cell targeted therapeutics in clinical development

  2013cites this paper
• Ofatumumab for a rituximab‐allergic child with chronic‐relapsing paraneoplastic opsoclonus–myoclonus

  2012cites this paper
• Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

  2012cites this paper
• Current and Emerging Treatments for Chronic Lymphocytic Leukaemia

  2012cites this paper
• Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

  2011cites this paper
• B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.

  2011cites this paper
• Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis

  2011cites this paper
• rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

  2011cites this paper
• Anti‐CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders

  2011cites this paper
• Chapter 2 B Lymphocytes in Cancer Immunology

  2011cites this paper
• A Retrospective Review of the Frequency and Nature of Acute Hypersensitivity Reactions at a Medium-Sized Infusion Center: Comparison to Reported Values and Inconsistencies Found in Literature

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Monoclonal antibody therapy in multiple sclerosis

  2010cites this paper
• Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

  2010cites this paper
• New Insights of an Old Defense System: Structure, Function, and Clinical Relevance of the Complement System

  2010cites this paper
• A Primate View on Multiple Sclerosis

  2010cites this paper
• Management of ANCA-associated vasculitis: Current trends and future prospects

  2010cites this paper
• The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.

  2010cites this paper
• Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

  2010cites this paper
• Compréhension et modulation des mécanismes d'action des anticorps monoclonaux thérapeutiques

  2010influential citation
• Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

  2010cites this paper
• Unauthorized reproduc Re-evaluation of biologic therapies in systemic lupus erythematosus

  2010cites this paper
• Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.

  2010cites this paper
• Treating multiple sclerosis with monoclonal antibodies: a 2010 update

  2010cites this paper
• Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases.

  2010cites this paper
• Ofatumumab in the treatment of chronic lymphocytic leukemia.

  2010cites this paper
• Pharmacotherapy for multiple sclerosis: progress and prospects.

  2009cites this paper
• Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy

  2009cites this paper
• Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.

  2009cites this paper
• Innate immune checkpoint inhibitors for treatment of Diffuse Large B-cell Lymphoma

  year unknowncites this paper